Breast Cancer Clinical Trial
— Medifocus301Official title:
Randomized Pivotal Trial to Assess the Safety and Efficacy of Preoperative Focused Microwave Thermotherapy Plus Preoperative Chemotherapy Versus Preoperative Chemotherapy Alone for Cytoreduction of Large Breast Cancer in Female Patients With Intact Breast
The purpose of this randomized Phase III study is to determine whether preoperative focused microwave heat treatment and chemotherapy combined are more effective than preoperative chemotherapy alone in the treatment of large breast cancer tumors in the intact breast. Combining heat with chemotherapy before surgery might shrink the tumor so that it can be removed in a breast conserving surgery (lumpectomy) instead of a mastectomy.
Status | Recruiting |
Enrollment | 238 |
Est. completion date | December 2016 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subjects must fulfill all of the following criteria to be eligible to participate in the study unless a specific waiver is requested by the investigator, agreed to by the sponsor, and documented for the study records. This protocol does not supersede Institutional IRB requirements for patient eligibility. 1. Female subject must be 18 years of age or older. 2. Subject must have adequate cognitive function to understand and sign the IRB/EC - approved informed consent prior to the performance of any study-specific procedure. 3. The subject must be at no risk for pregnancy either postmenopausal for at least one year, surgically sterile (i.e. hysterectomy), using two forms of birth control one being barrier method or practicing abstinence throughout the length of the study. The subject must also have a negative serum pregnancy test prior to any study-specific procedure. 4. Subject must have diagnosis by core biopsy of primary breast cancer, invasive ductal carcinoma or invasive lobular carcinoma, clinical tumor size 3.5 cm or greater, tumor classification T2 or T3, clinically node positive (N1, N2) or node negative (N0) by clinical exam, CT scan, or ultrasound, with distant metastasis (M1) or without distant metastasis (M0), with an indication for mastectomy. 5. Primary tumor must be measurable on breast ultrasound (US). 6. Primary tumor must be measurable by clinical exam. 7. Subject is a candidate for mastectomy and is eligible for neoadjuvant treatment. 8. Subject is a candidate for preoperative anthracycline-based combination chemotherapy. 9. Subject has a life expectancy of 6 months or more. 10. Karnofsky Score > 70. Exclusion Criteria: - Subjects meeting any of the following criteria will be excluded from the study unless a specific waiver is requested by the investigator, agreed to by the sponsor, and documented appropriately for the study records. This protocol does not supersede Institutional IRB requirements for patient eligibility: 1. Pregnant or lactating subject. 2. Mentally unable to participate in the study successfully because they are unable to understand the informed consent or unable to comply with the required study procedures. 3. Currently has breast implants. 4. Bilateral breast cancer. 5. Subjects with malignant breast tumors other than invasive ductal or invasive lobular carcinomas. 6. Subject is a candidate for breast conservation at enrollment. 7. Unable to tolerate prone position or breast compression. 8. Clinically significant heart disease, pacemakers, or defibrillators. 9. Bleeding disorders. Laboratory evidence of coagulopathy (PT, INR > 1.5; PTT > 1.5) or those who are receiving anticoagulants. 10. Thrombocytopenia (platelet count less than 100,000/mm3). 11. Renal insufficiency (BUN > 30 mg/dlan/or serum creatinine > 1.9 mg/dl). 12. Liver disease (bilirubin > 2.0 mg/dl and or > 2 fold increase of transaminases). 13. Diagnosis of cancer made by lumpectomy or incisional biopsy. 14. Contraindications to chemotherapy. 15. Clinical tumor fixation to the pectoralis major muscle or presence of skin nodules, involvement of the nipple. 16. Breast cancer with a high probability of extensive intra-ductal in situ disease (extensive DCIS or LCIS). 17. Multicentric disease (no satellite tumors greater than 2 cm diameter and no greater than 1.5 cm from the primary tumor as measured from the edge of the satellite tumor to the nearest edge of the primary tumor). 18. Prior history of collagen vascular disease. 19. Previous participation in Celsion Corporation study 201 or 202. 20. Subject has participated in an investigation drug or device trial 30 days prior to the screening visit or plans to enroll in an investigational drug or device trial at any time during this study. However current participation in another clinical study involving imaging is not exclusion. 21. Subject has a history of drug or alcohol abuse in the last 12 months. 22. Non-glandular breast cancers |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Ville-Marie Medical Centre | Montreal | Quebec |
United States | Dr. William Dooley | Oklahoma City | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
Medifocus, Inc. |
United States, Canada,
Dooley WC, Vargas HI, Fenn AJ, Tomaselli MB, Harness JK. Focused microwave thermotherapy for preoperative treatment of invasive breast cancer: a review of clinical studies. Ann Surg Oncol. 2010 Apr;17(4):1076-93. doi: 10.1245/s10434-009-0872-z. Epub 2009 Dec 22. — View Citation
Vargas HI; Dooley WC; Fenn AJ; Tomaselli MB; and Harness JK. Study of preoperative focused microwave phased array thermotherapy in combination with neoadjuvant anthracycline-based chemotherapy for large breast carcinomas. Cancer Therapy. 2007;5B:401-408. Available; http://www.cancer-therapy.org/CT5B/pdf/45._Vargas_et_al,_401-408.pdf. Accessed November 25, 2007. (background for protocol)
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tumor Shrinkage (ultrasound) | Evaluate the efficiency of preoperative focused microwave thermotherapy as an adjunct to chemotherapy to increase the ultrasound-measured absolute mean tumor percent shrinkage by volume over that achieved by SOC preoperative chemotherapy. | Prior to Surgery, on average 4 months from the start of treatment | No |
Secondary | Conversion Rate to Breast Conservation (surgeon recommended) | Evaluate the potential benefits of this combination treatment to increase the absolute rate for which the surgeon can recommend breast conservation (lumpectomy or partial mastectomy) over that achieved using standard of care preoperative chemotherapy alone. | Prior to Mastectomy Recommendation, on average 4 months from the start of treatment | No |
Secondary | Tumor Shrinkage (Clinical) | Evaluate the potential benefits of this combination treatment to increase the clinical (caliper-measured) absolute mean tumor shrinkage by area over that achieved by SOC preoperative chemotherapy | Prior to Surgery, on average 4 months from the start of treatment | No |
Secondary | Tumor Shrinkage (Mammography) | Evaluate the potential benefits of the combination treatment to increase the absolute mean tumor shrinkage by area on mammography over the achieved by SOC preoperative chemotherapy | Prior to Surgery, on average 4 months from the start of treatment | No |
Secondary | Tumor Shrinkage (MRI) | Evaluate the potential benefits of this combination treatment to increase the absolute mean tumor shrinkage by volume based on magnetic resonance imaging (MRI) over that achieved by SOC preoperative chemotherapy. | Prior to Surgery, on average 4 months from the start of treatment | No |
Secondary | Tumor Necrosis (pathology) | Evaluate the potential benefits of this combination treatment to increase the absolute mean percent localized pathologic tumor cell kill by volume over that achieved by SOC preoperative chemotherapy. | After Surgery, on average 5 months from the start of treatment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |